Chinese herbal medicines for hypercholesterolemia

被引:36
作者
Liu, Zhao Lan [1 ]
Liu, Jian Ping [1 ]
Zhang, Anthony Lin [2 ]
Wu, Qiong [3 ]
Ruan, Yao
Lewith, George
Visconte, Denise [4 ]
机构
[1] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing 100029, Peoples R China
[2] RMIT Univ, Sch Hlth Sci, Discipline Chinese Med, Bundoora, Vic, Australia
[3] Beijing Univ Chinese Med, Sch Humanities, Beijing 100029, Peoples R China
[4] Primary Med Care, Complementary & Integrated Med Res Unit, Southampton, Hants, England
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2011年 / 07期
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; SUGAR-CANE POLICOSANOL; CORONARY-HEART-DISEASE; PLASMA-CHOLESTEROL; RANDOMIZED-TRIALS; PLANT STEROLS; DOUBLE-BLIND; QUALITY; COMBINATION; EFFICACY;
D O I
10.1002/14651858.CD008305.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Hypercholesterolemia is an important key contributory factor for ischemic heart disease and is associated with age, high blood pressure, a family history of hypercholesterolemia, and diabetes. Chinese herbal medicines have been used for a long time as lipid-lowering agents. Objectives To assess the effects of Chinese herbal medicines on hypercholesterolemia. Search strategy We searched the following databases: The Cochrane Library (issue 8, 2010), MEDLINE (until July 2010), EMBASE (until July 2010), Chinese BioMedical Database (until July 2010), Traditional Chinese Medical Literature Analysis and Retrieval System (until July 2010), China National Knowledge Infrastructure (until July 2010), Chinese VIP Information (until July 2010), Chinese Academic Conference Papers Database and Chinese Dissertation Database (until July 2010), and Allied and Complementary Medicine Database (until July 2010). Selection criteria We considered randomized controlled clinical trials in hypercholesterolemic participants comparing Chinese herbal medicines with placebo, no treatment, and pharmacological or non-pharmacological interventions. Data collection and analysis Two review authors independently extracted data and assessed the risk of bias. We resolved any disagreements with this assessment through discussion and a decision was achieved based by consensus. We assessed trials for the risk of bias against key criteria: random sequence generation, allocation concealment, blinding of participants, incomplete outcome data, selective outcome reporting and other sources of bias. Main results We included 22 randomized trials (2130 participants). The mean treatment duration was 2.3 +/- 1.3 months (ranging from one to six months). Twenty trials were conducted in China and 18 trials were published in Chinese. Overall, the risk of bias of included trials was high or unclear. Five different herbal medicines were evaluated in the included trials, which compared herbs with conventional medicine in six comparisons (20 trials), or placebo (two trials). There were no outcome data in any of the trials on cardiovascular events and death from any cause. One trial each reported well-being (no significant differences) and economic costs. No serious adverse events were observed. Xuezhikang was the most commonly used herbal formula investigated. A significant effect on total cholesterol (two trial, 254 participants) was shown in favor of Xuezhikang when compared with inositol nicotinate (mean difference (MD) -0.90 mmol/L, 95% confidence interval (CI) -1.13 to -0.68). Authors' conclusions Some herbal medicines may have cholesterol-lowering effects. Our findings have to be interpreted with caution due to high or unclear risk of bias of the included trials.
引用
收藏
页数:111
相关论文
共 50 条
  • [41] Chinese herbal medicines for mild cognitive impairment A protocol for meta-analysis and trial sequential analysis
    Gu, Si-Chun
    Zhang, Li-Min
    Wang, Chun-Xu
    Qu, Yan-Jie
    Ma, Jing-Yi
    Zhen, Rong-Rong
    Gu, Chao
    Yuan, Can-Xing
    MEDICINE, 2021, 100 (39) : E27323
  • [42] Therapeutic effect of Chinese herbal medicines for post stroke recovery A traditional and network meta-analysis
    Han, Shi-You
    Hong, Zhi-You
    Xie, Yu-Hua
    Zhao, Yong
    Xu, Xiao
    MEDICINE, 2017, 96 (49)
  • [43] Chinese Herbal Medicines as an Adjunctive Therapy for Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
    Li, Bin
    Gan, Run
    Yang, Quanjun
    Huang, Jinlu
    Chen, Pengguo
    Wan, Lili
    Guo, Cheng
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2015, 2015
  • [44] Herbal Medicines for Allergic Rhinitis: a Systematic Review and Meta-analysis
    Minh Phuoc Hoang
    Chitsuthipakorn, Wirach
    Snidvongs, Kornkiat
    CURRENT ALLERGY AND ASTHMA REPORTS, 2021, 21 (04)
  • [45] Herbal medicines in functional dyspepsia-Untapped opportunities not without risks
    Gwee, Kok-Ann
    Holtmann, Gerald
    Tack, Jan
    Suzuki, Hidekazu
    Liu, Jinsong
    Xiao, Yinglian
    Chen, Min-Hu
    Hou, Xiaohua
    Wu, Deng-Chyang
    Toh, Clarissa
    Lu, Fang
    Tang, Xu-Dong
    NEUROGASTROENTEROLOGY AND MOTILITY, 2021, 33 (02)
  • [46] Acute adverse events from over-the-counter Chinese herbal medicines: a population-based survey of Hong Kong Chinese
    Kim, Jean H.
    Kwong, Elizabeth M. S.
    Chung, Vincent C. H.
    Lee, John C. O.
    Wong, Terry
    Goggins, William B.
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 13
  • [47] Traditional Japanese herbal medicines for treatment of odontopathy
    Yamaguchi, Kojiro
    FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [48] Capacity for Clinical Research on Herbal Medicines in Africa
    Willcox, Merlin
    Siegfried, Nandi
    Johnson, Quinton
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2012, 18 (06) : 622 - 628
  • [49] Treatment of Menopausal Symptoms with Herbal Medicines: A Review
    Wal, Pranay
    Singh, Indu
    Singh, Deependra
    Singh, Manju Rawat
    Wal, Ankita
    CURRENT WOMENS HEALTH REVIEWS, 2025, 21 (01)
  • [50] Herbal medicines in pediatrics What is evidence based?
    Laengler, A.
    Zuzak, T. J.
    Fricke, O.
    Seifert, G.
    MONATSSCHRIFT KINDERHEILKUNDE, 2019, 167 (09) : 768 - 777